Avara Pharmaceutical announced the acquisition of the GlaxoSmithKline (GSK) consumer healthcare manufacturing facility in Aiken, South Carolina is complete.
"The completion of this acquisition is an important component of our strategic plan. It expands our services by adding additional solid dose capability in the United States, which is in very high demand," Timothy C. Tyson, Chairman and CEO of Avara, said.
The transaction was expected to be completed on or before June 1, 2018.
Following completion of the transaction with GSK, Avara Pharmaceutical Services now has eight sites: three in the United States, including corporate headquarters, one in Puerto Rico, one in the UK, one in Ireland, one in Italy, and one in France.
"We continue with great confidence to add services and capabilities with complementary offerings in key regions. Each of our site teams have significant professional experience, state-of-the-art capabilities and long histories of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world," Tyson said.